All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-07-19T11:25:14.000Z

How to treat first relapse in lenalidomide-refractory MM?

By Marcia Rato, Joshua Reid, Zoe Brunn, Erika Roa
Featured
Clifton Mo
Omar Nadeem
Jul 19, 2021
Share:

Bookmark this article

During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We asked, How to treat first relapse in lenalidomide-refractory multiple myeloma (MM)?

During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We asked, How to treat first relapse in lenalidomide-refractory multiple myeloma (MM)?

In this podcast, Mo and Nadeem discuss factors to be considered with regimen options for patients with lenalidomide-refractory MM. They discuss cardiac risk factors, lines of therapy, prognosis, and end the podcast on the topic of new agents.

 

More about...
ASCOASCO 2021BortezomibBOSTONCANDORCarfilzomibDaratumumabDexamethasoneElotuzumabHigh-riskIKEMAIsatuximabLenalidomidePomalidomideRelapsed/refractory multiple myelomaSelinexor

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
17 votes - 13 days left ...

Related articles

Add bookmark

Selecting the best regimen at first relapse

During the Multiple Myeloma Hub Steering Committee Meeting in November 2022, key opinion leaders met to discuss how to select the best regimen at first relapse. The recorded discussion was chaired by...

Jan 25, 2023
Add bookmark

Selecting the best regimen at first relapse

During the Multiple Myeloma Hub Steering Committee Meeting in November 2022, key opinion leaders met to discuss how to select the best regimen at first...

Jan 25, 2023
Add bookmark

Sequencing treatments for relapsed/refractory multiple myeloma

A summary of the presentations discussing optimal therapies for patients in first and later relapse, that took place during the 6th World Congress on Controversies in Multiple Myeloma...

Jun 3, 2020
Add bookmark

Sequencing treatments for relapsed/refractory multiple myeloma

A summary of the presentations discussing optimal therapies for patients in first and later relapse, that took place during the 6th World...

Jun 3, 2020

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox